Global elimination of chronic hepatitis

DL Thomas - New England Journal of Medicine, 2019 - Mass Medical Soc
Global Elimination of Chronic Hepatitis | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

B Hajarizadeh, EB Cunningham, H Reid… - The lancet …, 2018 - thelancet.com
Background There are concerns around poorer response to direct-acting antiviral (DAA)
therapy for hepatitis C virus infection among people who use drugs. This systematic review …

HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma

GN Ioannou, PK Green, K Berry - Journal of hepatology, 2018 - Elsevier
Background & Aims It is unclear whether direct-acting antiviral (DAA) treatment-induced
sustained virologic response (SVR) reduces the risk of hepatocellular carcinoma (HCC) in …

Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection

Clinical infectious diseases, 2018 - academic.oup.com
Recognizing the importance of timely guidance regarding the rapidly evolving field of
hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) …

[HTML][HTML] Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection

AIHCVG Panel - Clinical infectious diseases: an official publication …, 2018 - ncbi.nlm.nih.gov
Recognizing the importance of timely guidance regarding the rapidly evolving field of
hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) …

Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores

GN Ioannou, LA Beste, PK Green, AG Singal… - Gastroenterology, 2019 - Elsevier
Background & Aims It is unclear if hepatocellular carcinoma (HCC) risk declines over time
after hepatitis C virus (HCV) eradication. We analyzed changes in HCC annual incidence …

Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges

TF Baumert, T Berg, JK Lim, DR Nelson - Gastroenterology, 2019 - Elsevier
Chronic infection with hepatitis C virus is a major cause of liver disease and hepatocellular
carcinoma worldwide. After the discovery of hepatitis C virus 3 decades ago, the …

Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial

S Kattakuzhy, C Gross, B Emmanuel… - Annals of internal …, 2017 - acpjournals.org
Background: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has
resulted in high rates of disease cure; however, not enough specialists currently are …

Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis

GN Ioannou, W Tang, LA Beste, MA Tincopa… - JAMA network …, 2020 - jamanetwork.com
Importance Deep learning, a family of machine learning models that use artificial neural
networks, has achieved great success at predicting outcomes in nonmedical domains …

Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification

GN Ioannou, P Green, KF Kerr, K Berry - Journal of hepatology, 2019 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) risk varies dramatically in patients with
cirrhosis according to well-described, readily available predictors. We aimed to develop …